Cost effectiveness of memantine in the treatment of moderately severe and severe Alzheimer's disease in Spain

被引：4
|
作者：
Antonanzas, F
Badenas, J
François, C
Guilhaume, C
机构：
[1] Univ La Rioja, Logrono, Spain
[2] H Lundbeck & Co AS, Barcelona, Spain
[3] H Lundbeck & Co AS, Paris, France
来源：
VALUE IN HEALTH | 2003年 / 6卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)61949-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：765 / 765
页数：1
相关论文
共 50 条
  • [1] Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease -: A Markov model in Finland
    François, C
    Sintonen, H
    Sulkava, R
    Rive, B
    [J]. CLINICAL DRUG INVESTIGATION, 2004, 24 (07) : 373 - 384
  • [2] Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer's disease in Spain (MEMORY study)
    Agueera-Ortiz, Luis F.
    [J]. REVISTA DE NEUROLOGIA, 2010, 51 (09) : 525 - 534
  • [3] A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease
    Kirby, Joanna
    Green, Colin
    Loveman, Ennna
    Clegg, Andrew
    Picot, Joanna
    Takeda, Andrea
    Payne, Elizabeth
    [J]. DRUGS & AGING, 2006, 23 (03) : 227 - 240
  • [4] A Systematic Review of the Clinical and Cost-Effectiveness of Memantine in Patients with Moderately Severe to Severe Alzheimer’s Disease
    Joanna Kirby
    Colin Green
    Emma Loveman
    Andrew Clegg
    Joanna Picot
    Andrea Takeda
    Elizabeth Payne
    [J]. Drugs & Aging, 2006, 23 : 227 - 240
  • [5] Cost Effectiveness of Memantine in Moderately Severe to Severe Alzheimer’s DiseaseA Markov Model in Finland
    Clément François
    Harri Sintonen
    Raimo Sulkava
    Benoît Rive
    [J]. Clinical Drug Investigation, 2004, 24 : 373 - 384
  • [6] COST-EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATE TO SEVERE ALZHEIMER'S DISEASE IN NORWAY
    Toumi, M.
    Lamure, M.
    Grishchenko, M.
    Cochran, J.
    Rive, B.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A370 - A370
  • [7] Treatment benefits of memantine in moderately severe to severe Alzheimer's disease patients with behavioural symptoms
    Wilcock, G.
    Ballard, C.
    Cooper, J.
    Loft, H.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 72 - 72
  • [8] Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway
    Rive, B.
    Aarsland, D.
    Grishchenko, M.
    Cochran, J.
    Lamure, M.
    Toumi, M.
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2012, 27 (06) : 573 - 582
  • [9] Memantine in Moderately-Severe-to-Severe Alzheimer's Disease A Postmarketing Surveillance Study
    Clerici, Francesca
    Vanacore, Nicola
    Elia, Antonietta
    Spila-Alegiani, Stefania
    Pomati, Simone
    Da Cas, Roberto
    Raschetti, Roberto
    Mariani, Claudio
    [J]. DRUGS & AGING, 2009, 26 (04) : 321 - 332
  • [10] Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands
    Hoogveldt, Bart
    Rive, Benoit
    Severens, Johan
    Maman, Khaled
    Guilhaume, Chantal
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2011, 7 : 313 - 317
12345